Publicado el 13 junio 2017

European Hematology Association (EHA) Congress: a poster will be presented

A poster entitled “Optimization Of Transduction Conditions With GMP Like Lentiviral Vectors For The Gene Therapy Of Piruvate Kinase Deficiecy” will be presented at European Hematology Association congress that will be hold in Madrid from 22nd to the 25th of June.

The authors of these posters are:

Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
Unidad Mixta de Terapias Avanzadas. Instituto de Investigación Sanitaria Fundación Jiménez
VIVEbiotech (responsible for the manufacturing of Lentiviral vectors)

As shown in the poster, this work has been finanzed with the support of the USA-based leader Company in Gene Therapy, Rocket Pharma.

Once this poster is presented, it will be shown at VIVEbiotech´s webpage.